Literature DB >> 25384853

[New ESH/ESC guidelines on arterial hypertension : what is new and what indications remain for renal denervation?].

P Groha1, S Kufner, I Ott, H Schunkert.   

Abstract

Arterial hypertension is one of the most common diseases in the western world and one of the most important risk factors for other cardiovascular diseases. Despite widespread therapeutic options, there is still a large proportion of patients with uncontrolled hypertension. The new European guidelines on hypertension give clear lines of action for diagnosis and treatment sorted into appropriate evidence levels based on current scientific data. Such evidence is still unclear for renal denervation so that no clear recommendations can be given.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25384853     DOI: 10.1007/s00059-014-4178-y

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  25 in total

1.  Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study.

Authors:  Daniel S Atherton; Nicholas L Deep; Farrell O Mendelsohn
Journal:  Clin Anat       Date:  2011-10-04       Impact factor: 2.414

2.  A dream yet to become true.

Authors:  Heribert Schunkert
Journal:  Hypertension       Date:  2007-05-07       Impact factor: 10.190

3.  Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA).

Authors:  Alberto Zanchetti; Michael Hennig; Regina Hollweck; Gene Bond; Rong Tang; Cesare Cuspidi; Gianfranco Parati; Rita Facchetti; Giuseppe Mancia
Journal:  Circulation       Date:  2009-09-08       Impact factor: 29.690

4.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.

Authors:  Robert W Schrier; Raymond O Estacio; Anne Esler; Philip Mehler
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

5.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 6.  Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses.

Authors:  George C Roush; Theodore R Holford; Achuta K Guddati
Journal:  Hypertension       Date:  2012-04-23       Impact factor: 10.190

7.  Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994).

Authors:  J Coresh; G L Wei; G McQuillan; F L Brancati; A S Levey; C Jones; M J Klag
Journal:  Arch Intern Med       Date:  2001-05-14

Review 8.  Established risk factors and coronary artery disease: the Framingham Study.

Authors:  P W Wilson
Journal:  Am J Hypertens       Date:  1994-07       Impact factor: 2.689

9.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more
  1 in total

1.  The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study.

Authors:  Ayman Abdelhady; Said Khader; Samy Sinnuqrut; Abdullah Albow
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.